Pathology Research International

Pathology Research International / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 569609 | 5 pages |

Malignant Mixed Mullerian Tumor: An Immunohistochemical Study

Academic Editor: Paulette Mhawech-Fauceglia
Received03 May 2012
Revised19 May 2012
Accepted22 May 2012
Published10 Jul 2012


Malignant mixed Mullerian tumor (MMMT) is an uncommon aggressive neoplasm composed of both malignant epithelial and mesenchymal components. In this study, immunohistochemical stains of germ cell markers, including SALL4, OCT3/4, glypican-3, and alpha-fetal protein (AFP), and CDX2 were performed in a series of MMMTs. SALL4 nuclear immunoreactivity was detected in 6 out of 19 cases (33%). The staining extent ranged from focal to extensive. The staining intensity was usually intermediate to strong (the score ranged from 1.5 to 3, and average score was 2.3 ± 0.5 in the positive cases). In addition, glypican-3 cytoplasmic reactivity was detected in 14 out of 16 cases (88%) with a mean score of 1.8 ± 0.7 (score ranging from 1 to 3). In contrast, OCT3/4 was only positive in 1 out of 19 cases and AFP in 2 out of 18 cases (11%). In summary, SALL4 and glypican-3 were frequently expressed in a subset of MMMTs. Their roles in the pathogenesis and biology of MMMT are yet to be determined. MMMT should be included in the differential diagnosis when a tumor is positive for SALL4 and/or glypican-3.

1. Introduction

Malignant mixed Mullerian tumor (MMMT) is an aggressive neoplasm that usually occurs in postmenopausal women and responds poorly to treatment [1]. Uterus and ovary are common sites for MMMT, though it can occur anywhere along the female genital tract and in the peritoneum. It is composed of both epithelial and mesenchymal components. The sarcomatous component can be homologous or heterologous depending on whether it is composed of native mesenchymal elements of the organ it arises from or other nonnative elements such as rhabdmyoblastic, osteogenic, chondroblastic, or lipoblastic element. The epithelial component can be endometrioid, undifferentiated, clear cell, or serous [1, 2]. The diagnosis of MMMT is usually not difficult; occasionally differentiation from various biphasic tumors such as mixed germ cell tumor can be difficult if the tumor occurred in relative younger age. In this study, we investigated the expression of germ cell markers including SALL4, OCT3/4, glypican-3, and AFP in a group of MMMTs. CDX2, a transcription factor regulating early enterogenic differentiation and found to express in some testicular germ cell tumor [3], was also evaluated in this group of MMMTs.

2. Material and Methods

Nineteen cases of MMMTs were retrieved from the database of the Hospital of the University of Pennsylvania, in which thirteen cases were from uterus, four from ovary, and two metastatic. One metastasis was from ovary to left paraaortic lymph nodes; the other was metastasized from uterus to rectal muscle. Immunohistochemistry was performed on 5 μm formalin-fixed paraffin-embedded tissue sections. The antibodies used were listed in Table 1. All immunostains were performed on the fully automated Leica Microsystems’ BondmaX Immunohistochemistry Staining System (Leica Microsystems, Bannockburn, IL).

AntigenCloneDilutionAntigen RetrievalManufacturer

SALL4Mouse clone EE-301: 100Citrate buffer, pH 6.0, 20 min at 100°CSanta Cruz
OCT3/4Goat polyclonal1: 150NO ARSanta Cruz
Glypican-3Mouse clone 1G121: 250Citrate buffer, pH 6.0, 20 minutes at 100°CCell Marque
AFPRabbit polyclonal1: 75NADako
CDX2Mouse clone CDX2-881: 10pH 9.0 EDTA, 20 min at 100°CBiogenex

Sections were incubated with respective primary antibody for 15 minutes at room temperature followed by detection of the antigen with a biotin-free polymeric horseradish peroxidase (HRP)-linker antibody conjugate system (Refine Polymer, Leica Microsystems) for 8 minutes at room temperature. Blocking of endogenous peroxidase was performed by incubating tissue sections in 3.0% H2O2 for 7 minutes.

Immunoreactivity was evaluated semiquantitatively under light microscope. Immunoreactivities of SALL4, OCT3/4, glypican-3, AFP, and CDX 2 were scored according to their extent and intensity of immunoreactivity. The final scores were achieved by the sum of intensity (0, negative; 1, weak intensity; 2, moderate intensity; 3, strong intensity) and extent of the immunoreactivity (0, negative; 1, <30%; 2, 30–70%; 3, >70%) divided by 2.

3. Results

MMMTs were composed of both carcinomatous and sarcomatous components, which might show morphological similarity to malignant mixed germ cell tumor (Figure 1(a)). The immunohistochemical results for SALL4, OCT3/4, glypican-3, CDX2, and AFP were listed in Table 2 and as follows.


Number of cases1819161818
Number of positive cases611432
% of positivity335881711
Score in positive cases1.522

3.1. SALL4

SALL4 nuclear stains were detected in 6 out of 18 cases (33%) with a score of 2.3 ± 0.5 in the positive ones. The extent of stain ranged from focal to diffuse, and the intensity of the stains was moderate to strong (Figure 1(b)). The positivity of SALL4 was usually detected in the epithelial components, which were usually high-grade serous adenocarcinoma. The mesenchymal component could show focal weak-to-moderate positivity. The benign endometrium, when present, was negative for SALL4 staining.

3.2. Glypican-3

Sixteen cases of MMMT were also stained for glypican-3, in which fourteen of them were positive (88%) for the cytoplasmic staining and the average score of stain was 1.8 ± 0.7 in the positive ones (Figure 1(c)). The extent of staining ranged from focal to diffuse, and intensity of the stains ranged from weak to strong. Glypican-3 reactivity was detected in both sarcomatous and poorly differentiated epithelial components. The benign endometrium, when present, was negative for glypican-3.

3.3. CDX2

Three out of 19 cases (16%) of MMMT were positive for CDX2 staining. The staining was in the nuclei of the epithelial components. The sarcomatous component was negative for CDX2. Two cases were focally positive, and the intensity of the stain was moderate (score 1.5). The remaining case showed diffuse and strong nuclear staining (score 3) (Figure 1(d)). Benign endometrium, when present, was negative for CDX2.

3.4. AFP

Two out of eighteen cases (11%) of MMMTs were also positive for AFP. One case was diffusely and the other case was focally positive. The intensities of the stain were moderate (score 2) (Figure 1(e)). The positive staining was in the epithelial component. Benign endometrium, when present, was negative for AFP.

3.5. OCT3/4

19 cases of MMMT were subject to OCT3/4 stain, and only one case showed focal nuclear positivity. The staining was mainly in the epithelial component (Figures 1(f) and 1(h)), which was a high-grade serous adenocarcinoma, while few mesenchymal cells were also positive (Figure 1(h)).

4. Discussion

MMMT is characterized by the presence of both carcinomatous and sarcomatous components with a poor prognosis [1]. Optimal cytoreduction seems to be the only therapy to have some impact on survival. No chemotherapy appears to show clear benefits [1]. MMMTs usually occur in postmenopausal women, however, may occasionally occur in relatively younger patients. Though most of germ cell tumors (GCTs) occur in younger patients, rarely can they occur in the postmenopausal women [46]. Some ovarian GCTs can sometimes be quite challenging in histological diagnosis. Mixed GCTs can mimic malignant mixed Mullerian tumors. YST can display multiple morphological patterns and can mimic different types of carcinoma such as clear cell carcinoma or endometrioid adenocarcinoma [7]. In difficult cases, various germ cell markers such as AFP and more recently described SALL4 and glypican-3 (GPC3) can be used to facilitate the diagnosis.

Recently, SALL4 has been reported to be positive not only in primitive germ cell tumors [8] but also in somatic malignancies [9, 10]. SALL4 is a zinc finger transcription factor and a homologue of drosophila spalt gene, which plays an important role in the specification of head and tail regions in the embryonic development [11]. In human, mutation of SALL4 causes the development of acro-renal-ocular and Okihiro syndromes [12]. SALL4 is important for the stem cell renewal and forms a regulatory circuit with OCT4, NANOG, and SOX2 to maintain embryonic stem cell pluripotency [13]. In addition to germ cell tumors, SALL4 has been shown to be expressed in somatic malignancy including lung [14], breast [9], leukemia [15] malignant rhabdoid tumor [16], and Wilm’s tumor [17]. SALL4 appears to involve the proliferation and the self-renewal of cancer cells [10, 14]. It has been shown that SALL4 is only weakly positive in three out of 45 clear cell carcinomas in ovaries. All of other types of tumors from ovaries are negative for this marker [8]. In this study, we showed that SALL4 expression in MMMTs was significantly higher compared to the reported incidence in other ovarian epithelial tumors. Whether the higher expression of SALL4 in MMMT contributes to its more aggressive behavior needs further investigation.

The high percentage of SALL4 positivity in the MMMTs prompted us to study OCT3/4, a key regulator in the maintenance of pluripotency in stem cells [18]. OCT3/4 is a stem cell marker and has been used in the differential diagnosis of germ cell tumors [19]. OCT3/4 has been found to express in bladder cancer [20] and renal medullary carcinoma [21]. In the bladder cancer, OCT 3/4 expression was correlated with tumor grade and recurrence [20]. In addition, it was found that the positive tumor cells were distributed in clusters instead of a more diffuse pattern [22].

In this study, we found only one tumor to be focally positive for this marker. One possibility for such focal expression is that these cells are present very focally in the tumors and it is difficult to get a glimpse of them due to specimen sampling issue.

Glypican-3 is a membrane-bound heparin sulfate proteoglycan. It is normally expressed in trophoblasts and a wide spectrum of fetal tissue and only limited expression in adult tissue [23]. It was first found to be overexpressed in YST by gene expression microarray [24]. Its expression was subsequently shown on routine histological section in YST [25]. Because of its selective expression in YST of mixed germ cell tumor, GPC3 can be used as a marker to differentiate YST among other germ cell elements. In this study, we showed that there was high percentage of positivity of GPC3 in both mesenchymal and epithelial components of MMMTs, indicating the stain for this marker has a limited role in the differential diagnosis between MMMT and YST. CDX2 is a homeobox domain containing transcription factor that is important for the development and differentiation of alimentary tract [26]. It has been shown to express in colonic epithelial tumors, and its role in tumorigenesis in colonic cancer has been speculated [27]. Despite the fact that CDX2 reactivity could be detected in small number of other non-GI tract epithelial tumors, it has been used as a diagnostic marker for tumor of GI tract origin in surgical pathology practice. We have demonstrated that variable CDX2 reactivity could be detected in the YST elements of mixed germ cell tumors with YST components in up to 40% of the cases and in mature colonic type epithelium in mature teratoma [3]. In this study, we showed low rate of positivity of this marker in MMMTs. In addition, we showed that two cases were also positive for AFP. AFP is a product of conceptus synthesized in yolk sac, liver, and GI tract in early fetal embryologic development. It is also characteristically expressed postnatally as fetal oncoprotein in YST and hepatocellular carcinoma as well as in some GI cancers such as gastric or colonic adenocarcinoma [2830].

In summary, SALL4 was expressed in a subset of MMMTs with a higher frequency than that of other ovarian tumors. The mechanism of SALL4 in the pathogenesis and its role in the prognosis of this tumor need further investigation. In addition, MMMTs were also frequently expressing glypican-3 but rarely CDX2 and AFP. MMMT should be considered in the differential diagnosis when tumor is positive for both SALL4 and/or glypican-3. Both SALL4 and glypican-3 though considered as marker for germ cell tumor should not be used alone in differentiating MMMT from germ cell tumors.


  1. R. Navarini and R. L. Pineda, “Malignant mixed müllerian tumors of the ovary,” Current Opinion in Obstetrics and Gynecology, vol. 18, no. 1, pp. 20–23, 2006. View at: Publisher Site | Google Scholar
  2. H. G. Muntz, M. A. Jones, B. A. Goff et al., “Malignant mixed mullerian tumors of the ovary: experience with surgical cytoreduction and combination chemotherapy,” Cancer, vol. 76, no. 7, pp. 1209–1213, 1995. View at: Publisher Site | Google Scholar
  3. Z. Bing, T. Pasha, J. E. Tomaszewski, and P. Zhang, “CDX2 expression in yolk sac component of testicular germ cell tumors,” International Journal of Surgical Pathology, vol. 17, no. 5, pp. 373–377, 2009. View at: Publisher Site | Google Scholar
  4. D. Kammerer-Doak, K. Baurick, W. Black, D. M. Barbo, and H. O. Smith, “Endodermal sinus tumor and embryonal carcinoma of the ovary in a 53- year-old woman,” Gynecologic Oncology, vol. 63, no. 1, pp. 133–137, 1996. View at: Publisher Site | Google Scholar
  5. M. T. Mazur, W. H. Talbot Jr., and A. Talerman, “Endodermal sinus tumor and mucinous cystadenofibroma of the ovary. Occurrence in an 82-year-old woman,” Cancer, vol. 62, no. 9, pp. 2011–2015, 1988. View at: Google Scholar
  6. C. Oh, A. Kendler, and E. Hernandez, “Ovarian endodermal sinus tumor in a postmenopausal woman,” Gynecologic Oncology, vol. 82, no. 2, pp. 392–394, 2001. View at: Publisher Site | Google Scholar
  7. P. B. Clement, R. H. Young, and R. E. Scully, “Endometrioid-like variant of ovarian yolk sac tumor. A clinicopathological analysis of eight cases,” American Journal of Surgical Pathology, vol. 11, no. 10, pp. 767–778, 1987. View at: Google Scholar
  8. D. Cao, S. Guo, R. W. Allan, K. H. Molberg, and Y. Peng, “SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma,” American Journal of Surgical Pathology, vol. 33, no. 6, pp. 894–904, 2009. View at: Publisher Site | Google Scholar
  9. D. Kobayashi, K. Kuribayshi, M. Tanaka, and N. Watanabe, “SALL4 is essential for cancer cell proliferation and is overexpressed at early clinical stages in breast cancer,” International Journal of Oncology, vol. 38, no. 4, pp. 933–939, 2011. View at: Publisher Site | Google Scholar
  10. J. Lu, Y. Ma, N. Kong et al., “Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia,” Leukemia, vol. 25, no. 7, pp. 1211–1213, 2011. View at: Publisher Site | Google Scholar
  11. G. Jurgens, “Head and tail development of the Drosophila embryo involves spalt, a novel homeotic gene,” The EMBO Journal, vol. 7, pp. 189–196, 1988. View at: Google Scholar
  12. J. Kohlhase, M. Heinrich, L. Schubert et al., “Okihiro syndrome is caused by SALL4 mutations,” Human Molecular Genetics, vol. 11, no. 23, pp. 2979–2987, 2002. View at: Google Scholar
  13. J. Zhang, W. L. Tam, G. Q. Tong et al., “Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1,” Nature Cell Biology, vol. 8, no. 10, pp. 1114–1123, 2006. View at: Publisher Site | Google Scholar
  14. D. Kobayashi, K. Kuribayashi, M. Tanaka, and N. Watanabe, “Overexpression of SALL4 in lung cancer and its importance in cell proliferation,” Oncology Reports, vol. 26, no. 4, pp. 965–970, 2011. View at: Publisher Site | Google Scholar
  15. C. Gao, N. R. Kong, and L. Chai, “The role of stem cell factor SALL4 in leukemogenesis,” Critical Reviews in Oncogenesis, vol. 16, no. 1-2, pp. 117–127, 2011. View at: Google Scholar
  16. J. Deisch, J. Raisanen, and D. Rakheja, “Immunohistochemical expression of embryonic stem cell markers in malignant rhabdoid tumors,” Pediatric and Developmental Pathology, vol. 14, no. 5, pp. 353–359, 2011. View at: Publisher Site | Google Scholar
  17. J. Deisch, J. Raisanen, and D. Rakheja, “Immunoexpression of SALL4 in wilms tumors and developing kidney,” Pathology and Oncology Research, vol. 17, pp. 639–644, 2011. View at: Publisher Site | Google Scholar
  18. R. Kekuda, P. D. Prasad, X. Wu et al., “Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta,” Journal of Biological Chemistry, vol. 273, no. 26, pp. 15971–15979, 1998. View at: Publisher Site | Google Scholar
  19. L. Cheng, “Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry,” Cancer, vol. 101, no. 9, pp. 2006–2010, 2004. View at: Publisher Site | Google Scholar
  20. P. Huang, J. Chen, L. Wang et al., “Implications of transcriptional factor, OCT-4, in human bladder malignancy and tumor recurrence,” Medical Oncology, vol. 29, pp. 829–834, 2012. View at: Publisher Site | Google Scholar
  21. P. Rao, N. M. Tannir, and P. Tamboli, “Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall,” American Journal of Surgical Pathology, vol. 36, no. 4, pp. 583–588, 2012. View at: Publisher Site | Google Scholar
  22. C. T. Jordan, M. L. Guzman, and M. Noble, “Cancer stem cells,” New England Journal of Medicine, vol. 355, no. 12, pp. 1253–1261, 2006. View at: Publisher Site | Google Scholar
  23. Y. Y. Xiang, V. Ladeda, and J. Filmus, “Glypican-3 expression is silenced in human breast cancer,” Oncogene, vol. 20, no. 50, pp. 7408–7412, 2001. View at: Publisher Site | Google Scholar
  24. J. Sugimura, R. S. Foster, O. W. Cummings et al., “Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis,” Clinical Cancer Research, vol. 10, no. 7, pp. 2368–2378, 2004. View at: Publisher Site | Google Scholar
  25. D. L. Zynger, M. J. Everton, N. D. Dimov, P. M. Chou, and X. J. Yang, “Expression of glypican 3 in ovarian and extragonadal germ cell tumors,” American Journal of Clinical Pathology, vol. 130, no. 2, pp. 224–230, 2008. View at: Publisher Site | Google Scholar
  26. D. Y. R. Stainier, “No organ left behind: tales of gut development and evolution,” Science, vol. 307, no. 5717, pp. 1902–1904, 2005. View at: Publisher Site | Google Scholar
  27. S. Bakaris, A. Cetinkaya, F. Ezberci, and H. Ekerbicer, “Expression of homeodomain protein CDX2 in colorectal adenoma and adenocarcinoma,” Histology and Histopathology, vol. 23, no. 7–9, pp. 1043–1047, 2008. View at: Google Scholar
  28. G. R. Hocking, M. Shembrey, D. Hay, and A. G. Ostor, “Alpha-fetoprotein-producing adenocarcinoma of the sigmoid colon with possible hepatoid differentiation,” Pathology, vol. 27, no. 3, pp. 277–279, 1995. View at: Publisher Site | Google Scholar
  29. K. Kurihara, F. Konishi, K. Kanazawa, T. Fujii, and K. Saito, “Alpha-fetoprotein-producing carcinoma of the colon: report of a case,” Surgery Today, vol. 27, no. 5, pp. 453–456, 1997. View at: Publisher Site | Google Scholar
  30. E. Ucar, E. Semerci, H. Ustun, T. Yetim, C. Huzmeli, and M. Gullu, “Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer,” Advances in Therapy, vol. 25, no. 10, pp. 1075–1084, 2008. View at: Google Scholar

Copyright © 2012 Zhanyong Bing et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

6356 Views | 912 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.